148 related articles for article (PubMed ID: 28250004)
1. Research in the heart of hematology: chronic myeloid leukemia 2017.
Hehlmann R
Haematologica; 2017 Mar; 102(3):418-421. PubMed ID: 28250004
[No Abstract] [Full Text] [Related]
2. Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.
Proschmann R; Baldow C; Rothe T; Suttorp M; Thiede C; Tauer JT; Müller MC; Hochhaus A; Roeder I; Glauche I
Haematologica; 2017 Feb; 102(2):e39-e42. PubMed ID: 27856510
[No Abstract] [Full Text] [Related]
3. Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.
Hu T; Ciccarelli BT
Leuk Res; 2014 Dec; 38(12):1399-400. PubMed ID: 25449686
[No Abstract] [Full Text] [Related]
4. Chromosomal aberrations and fusion genes in myeloid malignancies.
Gianfelici V; Lahortiga I; Cools J
Expert Rev Hematol; 2012 Aug; 5(4):381-93. PubMed ID: 22992233
[TBL] [Abstract][Full Text] [Related]
5. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
Malcikova J; Razga F; Jurcek T; Dvorakova D; Zackova D; Toskova M; Sebejova L; Smardova J; Oltova A; Vankova G; Jurackova L; Trbusek M; Pospisilova S; Mayer J; Racil Z
Leuk Lymphoma; 2013 Sep; 54(9):2083-7. PubMed ID: 23289360
[No Abstract] [Full Text] [Related]
6. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
[No Abstract] [Full Text] [Related]
7. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
8. Another piece of the puzzle--optimal TKI selection before treatment discontinuation in CML.
Wolf D
Eur J Haematol; 2015 Mar; 94(3):189-90. PubMed ID: 25712068
[No Abstract] [Full Text] [Related]
9. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
10. Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.
Valent P
Lancet Oncol; 2010 Nov; 11(11):1010-1. PubMed ID: 20965784
[No Abstract] [Full Text] [Related]
11. Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.
Bumm T; Deininger J; Newell AH; Lawce H; Olson S; Mauro M; Druker B; Deininger M
Leukemia; 2010 Aug; 24(8):1525-1528. PubMed ID: 20535153
[No Abstract] [Full Text] [Related]
12. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
[No Abstract] [Full Text] [Related]
13. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Cortes JE; Jorgensen JL; Wang W; Yin CC; You MJ; Jabbour E; Kantarjian HM; Medeiros LJ; Hu S
Leukemia; 2016 Jul; 30(7):1606-9. PubMed ID: 26837843
[No Abstract] [Full Text] [Related]
14. Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome.
Chakraborty R; Mukkamalla SK; Singam K; Calderon N
Korean J Intern Med; 2014 Nov; 29(6):827-9. PubMed ID: 25378984
[No Abstract] [Full Text] [Related]
15. Treating chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Gale RP; Goldman JM
Acta Haematol; 2013; 130(3):192-5. PubMed ID: 23774684
[No Abstract] [Full Text] [Related]
16. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
17. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.
Katagiri S; Umezu T; Ohyashiki JH; Ohyashiki K
Br J Haematol; 2013 Jan; 160(2):269-71. PubMed ID: 23116058
[No Abstract] [Full Text] [Related]
18. [Chronic myelogenous leukemia: diagnosis and treatment].
Demeter J; Poros A; Bödör C; Horváth L; Masszi T
Orv Hetil; 2016 Sep; 157(37):1459-68. PubMed ID: 27615196
[TBL] [Abstract][Full Text] [Related]
19. The second generation of BCR-ABL tyrosine kinase inhibitors.
Tauchi T; Ohyashiki K
Int J Hematol; 2006 May; 83(4):294-300. PubMed ID: 16757427
[TBL] [Abstract][Full Text] [Related]
20. [Cytogenetic and molecular monitoring of chronic myeloid leukemia].
Kajtár B; Méhes G; Jaksó P; Kereskai L; Iványi JL; Losonczy H; Egyed M; Tóth P; Tóth A; Gasztonyi Z; Dömötör M; Pajor L
Orv Hetil; 2006 May; 147(21):963-70. PubMed ID: 16812971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
